Guillain-Barré Syndrome (GBS) Treatment in Thailand

What is Guillain-Barré Syndrome (GBS)?

Guillain-Barré Syndrome (GBS) is a rare neurological disorder in which the immune system mistakenly attacks the peripheral nerves. This can disrupt nerve signals that control muscle movement and sensation, causing tingling, numbness, and progressive muscle weakness. Weakness often begins in the legs and may spread to the arms and upper body. In severe cases, GBS can cause paralysis, difficulty swallowing or breathing, and abnormalities in heart rate or blood pressure.

What is the Importance of Timely Treatment?

Guillain-Barré Syndrome (GBS) can progress rapidly over hours or days and may affect the muscles responsible for breathing, swallowing and movement. Prompt hospital assessment is essential to monitor respiratory function, heart rate, blood pressure and neurological changes. Intravenous immunoglobulin (IVIG) or plasma exchange may be recommended for eligible patients to reduce the immune-mediated nerve injury and improve recovery. Supportive care, including intensive care when necessary, helps manage potentially life-threatening complications.

What are the Common Symptoms of Guillain-Barré Syndrome (GBS)?

• Tingling or pins-and-needles sensations, particularly in the feet or hands
• Weakness that usually begins in both legs
• Difficulty walking, climbing stairs or standing
• Weakness spreading to the arms and upper body
• Loss or reduction of deep-tendon reflexes
• Muscle or nerve pain
• Difficulty with facial movements or facial weakness
• Difficulty speaking, chewing or swallowing
• Problems with coordination or balance
• Abnormal heart rate or blood-pressure fluctuations
• Difficulty breathing in severe cases
• Paralysis in severe or rapidly progressive disease

Causes and Risk Factors of Guillain-Barré Syndrome (GBS)

Causes

• GBS usually develops when an abnormal immune response damages peripheral nerves, often following an infection. Campylobacter jejuni, a bacterium that can cause gastrointestinal infection, is one recognised trigger.
• Other reported triggers include respiratory or gastrointestinal infections, as well as influenza, cytomegalovirus, Epstein-Barr virus, and Zika virus.
• In rare cases, GBS may occur after vaccination or surgery, although the absolute risk following vaccination is extremely low.

Risk Factors

• Recent gastrointestinal or respiratory infection
• Recent Campylobacter jejuni infection
• Certain viral infections, including CMV, EBV, influenza or Zika virus
• Older age
• Rarely, recent surgery or vaccination
• Previous GBS, although recurrence is uncommon

Latest Research and Technologies in the Treatment of Guillain-Barré Syndrome (GBS) in Thailand

• Current research into GBS focuses on understanding immune-mediated nerve damage, improving early diagnosis and identifying treatments that may improve functional recovery. IVIG and plasma exchange remain the established immunotherapies for eligible patients. Research into targeted immune therapies, including complement inhibition, continues, but these approaches are not established routine treatments for GBS.